Michael Andreeff Selected Research

Michael Andreeff Research Topics

Disease

174	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2024 - 01/2002
123	Neoplasms (Cancer) 12/2023 - 01/2002
110	Leukemia 11/2023 - 02/2002
20	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 06/2002
17	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2024 - 04/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2002
17	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2019 - 06/2002
16	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2002
16	Hematologic Neoplasms (Hematological Malignancy) 03/2021 - 01/2002
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
14	Hypoxia (Hypoxemia) 01/2023 - 08/2009
11	Acute Promyelocytic Leukemia 01/2022 - 03/2004
10	Lymphoma (Lymphomas) 01/2015 - 10/2004
9	Carcinogenesis 01/2022 - 09/2003
8	Philadelphia Chromosome 10/2011 - 04/2002
6	Blast Crisis (Blast Phase) 10/2015 - 02/2006
5	Inflammation (Inflammations) 10/2019 - 03/2006
5	Myeloid Leukemia (Leukemia, Myelocytic) 01/2017 - 01/2002
5	Glioma (Gliomas) 04/2013 - 04/2005
5	Mitochondrial Diseases (Mitochondrial Disease) 05/2008 - 12/2005
4	Disease Progression 01/2022 - 06/2008
4	AIDS-Related Complex (ARC) 01/2019 - 01/2011
4	Residual Neoplasm 01/2018 - 01/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010 - 10/2002
3	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 09/2002
3	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 06/2002
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 10/2018

Drug/Important Bio-Agent (IBA)

67	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2002
31	venetoclaxIBA 04/2024 - 03/2014
28	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 04/2002
20	TriterpenesIBA 11/2014 - 01/2002
15	bardoxoloneIBA 04/2012 - 01/2002
14	Phosphotransferases (Kinase)IBA 02/2023 - 06/2003
14	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 02/2008
13	LigandsIBA 01/2023 - 07/2002
12	bardoxolone methylIBA 11/2014 - 01/2002
11	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 06/2013
11	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 07/2002
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2018 - 05/2002
10	CaspasesIBA 11/2014 - 12/2002
10	SurvivinIBA 08/2013 - 09/2003
10	AcidsIBA 11/2007 - 09/2003
9	fms-Like Tyrosine Kinase 3IBA 01/2023 - 04/2006
9	Tyrosine Kinase InhibitorsIBA 04/2022 - 06/2003
9	Oxygen (Dioxygen)IBA 10/2021 - 07/2008
9	ABT-737IBA 09/2021 - 11/2006
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 06/2006
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 02/2006
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
8	CytokinesIBA 01/2020 - 09/2002
7	EnzymesIBA 01/2023 - 01/2009
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 03/2009
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 04/2005
7	bcr-abl Fusion ProteinsIBA 01/2016 - 07/2002
7	fludarabineIBA 07/2015 - 04/2002
6	Decitabine FDA Link 01/2022 - 08/2003
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 03/2006
6	MicroRNAs (MicroRNA)IBA 01/2018 - 03/2008
6	Messenger RNA (mRNA)IBA 01/2018 - 06/2002
6	nutlin 3IBA 01/2017 - 08/2006
5	MethyltransferasesIBA 01/2023 - 06/2009
5	NF-kappa B (NF-kB)IBA 01/2022 - 01/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 06/2009
5	selinexorIBA 11/2020 - 01/2015
5	Adenosine Triphosphate (ATP)IBA 01/2013 - 12/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2012 - 08/2005
5	EstersIBA 12/2010 - 01/2002
5	PPAR gammaIBA 06/2010 - 07/2002
4	Drug CombinationsIBA 01/2023 - 05/2014
4	NucleophosminIBA 01/2023 - 12/2013
4	Glutathione (Reduced Glutathione)IBA 01/2023 - 10/2005
4	Galectin 3 (LGALS3)IBA 06/2019 - 04/2016
4	Rituximab (Mabthera)FDA Link 01/2019 - 05/2003
4	CateninsIBA 01/2019 - 04/2014
4	ChemokinesIBA 04/2016 - 12/2006
4	ProdrugsIBA 04/2016 - 01/2011
4	Bortezomib (Velcade)FDA Link 02/2016 - 10/2003
4	Cyclin D1IBA 01/2015 - 09/2003
4	Monoclonal AntibodiesIBA 03/2014 - 06/2005
4	Caspase 8 (Caspase-8)IBA 02/2014 - 05/2005
4	Antisense OligonucleotidesIBA 08/2013 - 02/2009
4	Chemokine CXCL12IBA 01/2013 - 04/2005
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2012 - 04/2002
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2010 - 04/2005
4	Mitogen-Activated Protein KinasesIBA 03/2010 - 05/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008 - 09/2002
4	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 03/2004
3	snake venom protein C activatorIBA 10/2023 - 01/2019
3	DS-5272IBA 03/2023 - 01/2020
3	Aurora KinasesIBA 02/2023 - 10/2008
3	Lysine (L-Lysine)FDA Link 01/2023 - 01/2021
3	Radioisotopes (Radionuclides)IBA 02/2022 - 01/2018
3	GD2 gangliosideIBA 01/2022 - 06/2012

Therapy/Procedure

96	Therapeutics 01/2024 - 04/2002
46	Drug Therapy (Chemotherapy) 01/2024 - 03/2003
5	Induction Chemotherapy 01/2022 - 03/2003
4	Transplantation 01/2022 - 01/2012
4	Radiotherapy 01/2021 - 08/2004
4	Stem Cell Transplantation 01/2018 - 12/2011
3	Immunotherapy 01/2022 - 04/2003